Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Clinical trial NCT05685004 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05685004
- Sponsor
- TVAX Biomedical
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-15
- Primary completion
- 2026-12-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.